南韩将启动新冠疫苗交叉接种临床试验
据《韩联社》报道,南韩疾病管理厅下属国立保健研究院计划启动新冠疫苗交叉接种临床试验,将为已接种第一针阿斯利康(AZN.US)疫苗的约500名人士,接种第二针辉瑞(PFE.US)等其他疫苗。
当局表示,相关结果将用以提升疫苗接种的安全性和有效性,初步计划面向约400至500人进行临床试验。
南韩目前禁止交叉接种疫苗,但德国和法国已决定分别向60岁和55岁以下第一针已接种阿斯利康疫苗的人群,使用辉瑞或莫德纳等基於mRNA技术研制的疫苗接种第二针,英国、意大利、俄罗斯、中国等亦已就此开展临床试验。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.